Like Merck, AstraZeneca (NYSE:AZN) doesn’t quite ring a bell as a major influenza play. But, it’s in the game, through its MedImmune subsidiary (which AstraZeneca purchased in 2007).
MedImmune is the maker of the popular FluMist, which is administered as a nasal spray rather than an injection. Sales of FluMist totaled $145 million in the third quarter, and $161 million for all of last year.
As of this writing, James Brumley did not hold a position in any of the aforementioned securities.